INJECTION OF SUCCESS Vaccine-focused biotechnology company Bavarian Nordic is at the heart of developing and manufacturing vaccines for infectious diseases and lifethreatening illnesses. EmmaJane Batey spoke to CEO Anders Hedegaard to learn more about the company’s growth plans and major global contracts. 186 Industry Europe
E
stablished in Denmark in 1994, vaccinefocused biotechnology company Bavarian Nordic has rapidly and strategically grown to become a leading name in the development and manufacture of vaccines for the prevention and treatment of infectious diseases and life-threatening illnesses. Listed on the Copenhagen Stock Exchange, Bavarian Nordic has over 450 employees and 2012 expected revenues of DKK900. With manufacturing, R&D and sales facilities in Denmark, Germany, and the USA, Bavarian Nordic has a strong global footprint.
Divided into three core competences, Bavarian Nordic offers vaccines in the fields of cancer, biodefence and infectious diseases.
Government growth A major element in its ongoing success is the company’s highly valuable long-term contract with the US Government for the development and manufacture of a smallpox vaccine. CEO Anders Hedegaard told Industry Europe, “Our development of a vaccine against smallpox is the very core of the company. Post 9-11, the US Government
